曲美他嗪对慢性肺源性心脏病患者心肺功能及生命质量的影响

目的探讨曲美他嗪对慢性肺源性心脏病(肺心病)患者心肺功能及生命质量(QOL)的影响。方法连续选取2010年9月—2012年3月在武汉市武昌医院呼吸内科住院治疗的慢性肺心病患者96例,将其按随机数字表法分为观察组46例和对照组50例。对照组予以常规治疗,观察组在此基础上加用曲美他嗪,12周为1个疗程。观察两组患者治疗前后第一秒用力呼气容积占用力肺活量百分比(FEV1/FVC)、最大呼气中段流速(MMEF)、血浆氨基末端脑钠肽前体(NT-proBNP)水平及QOL评分。结果治疗后观察组患者FEV1/FVC和MMEF高于对照组,NT-proBNP及QOL评分低于对照组(P0.01)。结论曲美他嗪能改善慢性肺心病患者心肺功能,提高其QOL。

Influence of Trimetazidine on Cardio-respiratory Function and Quality of Life in Patients with Chronic Pulmonary Heart Disease

Objective To investigate the influence of trimetazidine on cardio - respiratory function and quality of life （QOL） in patients with chronic pulmonary heart disease. Methods 96 patients with chronic pulmonary heart disease admitted to Wuchang Hospital of Wuhan from September 2010 to March 2012 were divided into groups observation （46 cases） and control （50 cases）, according to the random number table. Control group was given conventional treatment, observation group was given trimetazidine on the basis of conventional treatment, both treated for 12 weeks. The forced expiratory volume in the first second to forced vital capacity （FEVI/FVC） , percentage of maximal mid expiratory flow rate （MMEF） , plasma N -terminal pro brain natriuretic peptide precursor （ NT - proBNP） and QOL score between two groups were compared. Results After treatment, the level of FEVJFVC, MMEF in observation group were higher than those of control group, the level of NT- proBNP and QOL score lower （ P 〈 0. 01 ）. Conclusion Trimetazidine can improve the cardio - respiratory function and increase QOL score in pa- tients with chronic pulmonary heart disease.